Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Brakemeier, Susanne [VerfasserIn]   i
 Arns, Wolfgang [VerfasserIn]   i
 Lehner, Frank [VerfasserIn]   i
 Witzke, Oliver [VerfasserIn]   i
 Vonend, Oliver [VerfasserIn]   i
 Sommerer, Claudia [VerfasserIn]   i
 Mühlfeld, Anja [VerfasserIn]   i
 Rath, Thomas [VerfasserIn]   i
 Schuhmann, Robert [VerfasserIn]   i
 Zukunft, Bianca [VerfasserIn]   i
 Kroeger, Irena [VerfasserIn]   i
 Porstner, Martina [VerfasserIn]   i
 Budde, Klemens [VerfasserIn]   i
Titel:Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program
Titelzusatz:results of a prospective randomized multicenter study (SENATOR)
Verf.angabe:Susanne Brakemeier, Wolfgang Arns, Frank Lehner, Oliver Witzke, Oliver Vonend, Claudia Sommerer, Anja Mühlfeld, Thomas Rath, Robert Schuhmann, Bianca Zukunft, Irena Kroeger, Martina Porstner, Klemens Budde
E-Jahr:2019
Jahr:September 19, 2019
Fussnoten:Gesehen am 14.04.2020
Titel Quelle:Enthalten in: PLOS ONE
Ort Quelle:San Francisco, California, US : PLOS, 2006
Jahr Quelle:2019
Band/Heft Quelle:14(2019,9) Artikel-Nummer e0222730, 17 Seiten
ISSN Quelle:1932-6203
Abstract:Early conversion to everolimus was assessed in kidney transplant recipients participating in the Eurotransplant Senior Program (ESP), a population in whom data are lacking. The SENATOR multicenter study enrolled 207 kidney transplant recipients undergoing steroid withdrawal at week 2 post-transplant (ClinicalTrials.gov [NCT00956293]). At week 7, patients were randomized (1:2 ratio) to continue the previous calcineurin inhibitor (CNI)-based regimen with mycophenolic acid (MPA) and cyclosporine or switch to a CNI-free regimen with MPA, everolimus (5-10 ng/mL) and basiliximab at weeks 7 and 12, then followed for 18 weeks to month 6 post-transplant. The primary endpoint was estimated GFR (eGFR). At week 7, 77/207 (37.2%) patients were randomized (53 everolimus, 24 control). At month 6, eGFR was comparable: 36.5±10.8ml/min with everolimus versus 42.0±13.0ml/min in the control group (p = 0.784). Discontinuation due to adverse events occurred in 27.8% of everolimus-treated patients and 0.0% of control patients (p = 0005). Efficacy profiles showed no difference. In conclusion, eGFR, safety and efficacy outcomes at month 6 post-transplant showed no difference between groups. The everolimus group experienced a higher rate of discontinuation due to adverse events. However, the high rate of non-randomization is highly relevant, indicating this to be a somewhat unstable patient population regardless of treatment.
DOI:doi:10.1371/journal.pone.0222730
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1371/journal.pone.0222730
 Volltext: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222730
 DOI: https://doi.org/10.1371/journal.pone.0222730
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Adverse events
 Creatinine
 Elderly
 Geriatrics
 Immunosuppressives
 Renal system
 Renal transplantation
 Steroids
K10plus-PPN:1694421279
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68563792   QR-Code
zum Seitenanfang